[ExI] Fwd: May Cryonics issue

Rafal Smigrodzki rafal.smigrodzki at gmail.com
Mon May 28 21:04:14 UTC 2012

Forgot to press the reply-to-all button

---------- Forwarded message ----------
From: Rafal Smigrodzki <rafal.smigrodzki at gmail.com>
Date: Mon, May 28, 2012 at 5:03 PM
Subject: Re: [ExI] May Cryonics issue
To: david pizer <pizerdavid at yahoo.com>

You are right, David, that the key to success in the cryonics business
is to drum up more business and reduce waste .... but the devil is in
the details. Massively (percentage-wise) cutting prices for neuro and
slightly (again, percentage-wise) increasing prices for whole body
should definitely achieve both, even if the total average
per-suspension intake is only slightly increased. Neuro patients are
more likely to be price-sensitive, so cutting their price will
increase their numbers. Since keeping them frozen costs nothing (until
the whole/neuro ratio drops below 0.8), there will be no net spending
increase for Alcor. Whole-body patients are less price sensitive
(since they already chose a more expensive but less effective
procedure), so they will not abandon Alcor in droves after a price
increase. Dewar utilization will improve.

Would you expect different results? Specifically, do you expect a
different effect of such a price change on the number of neuro
signups, number of whole body signups and average dewar utilization?


Rafal Smigrodzki, MD-PhD
Senior Scientist,
Gencia Corporation
706 B Forest St.

Charlottesville, VA 22903

tel: (434) 295-4800

fax: (434) 295-4951

This electronic message transmission contains information from the
biotechnology firm of Gencia Corporation which may be confidential or
privileged. The information is intended to be for the use of the
individual or entity named above. If you are not the intended
recipient, be aware that any disclosure, copying, distribution or use
of the contents of this information is prohibited. If you have
received this electronic transmission in error, please notify us by
telephone (434-295-4800) or by electronic mail
(fportell at genciabiotech.com) immediately.

More information about the extropy-chat mailing list